Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators
- 23 July 2019
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (17), 2443-2447
- https://doi.org/10.1016/j.bmcl.2019.07.035
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education and Science of the Russian Federation (4.5821.2017/8.9)
- Russian Science Foundation (14-25-00139)
This publication has 31 references indexed in Scilit:
- AMP-activated protein kinase activator AICAR acutely lowers blood pressure and relaxes isolated resistance arteries of hypertensive ratsJournal of Hypertension, 2012
- Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes ComplicationsDiabetes, 2012
- Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesityJCI Insight, 2011
- The AMPK signalling pathway coordinates cell growth, autophagy and metabolismNature, 2011
- Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activityBiochemical and Biophysical Research Communications, 2011
- Library of Biphenyl Privileged Substructures using a Safety-Catch Linker ApproachJournal of Combinatorial Chemistry, 2008
- TLR4 links innate immunity and fatty acid–induced insulin resistanceJCI Insight, 2006
- Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndromeCell Metabolism, 2006
- Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic ratsJournal of Hypertension, 2003
- The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged SubstructuresChemical Reviews, 2003